Everolimus-Induced Elevated Cholesterol and Triglycerides

Everolimus (Zortress® for transplant indications in the U.S.) and sirolimus inhibit the mTOR pathway and can increase serum cholesterol and triglycerides. In liver and kidney transplant practice, dyslipidemia is common and multifactorial—driven by immunosuppressant choice and exposure, corticosteroids, calcineurin inhibitors, pre-existing diabetes/obesity, and post-transplant lifestyle changes. Because dyslipidemia contributes to long-term cardiovascular risk, programs commonly integrate lipid monitoring into routine post-transplant surveillance, escalating therapy when targets are not met while maintaining adequate immunosuppression. ^{[1] [6] [8]}

Both sirolimus and everolimus are associated with elevations in cholesterol and triglycerides. In liver transplantation cohorts, sirolimus-related hyperlipidemia has been described, and everolimus reviews in liver transplantation similarly emphasize dyslipidemia as a clinically relevant adverse effect requiring monitoring and management. In practice, “which is worse” is often less important than individualized risk: baseline lipids, diabetes, steroid exposure, diet/weight changes, and interacting medications can determine how severe lipid changes become and how aggressively they must be treated. ^{[3] [4] [8]}

Obtain a baseline fasting lipid panel before starting or converting to an mTOR inhibitor. Recheck approximately 4–8 weeks after initiation or dose change, then every 3–6 months once stable, or sooner if severe elevations occur. Track the mTOR inhibitor trough level (exposure), concomitant steroids, calcineurin inhibitors, weight change, diabetes control, alcohol intake (especially relevant for triglycerides), and secondary causes of dyslipidemia. Many transplant dyslipidemia reviews emphasize aligning lipid monitoring with immunosuppression review because medication exposure and drug interactions can drive abrupt metabolic changes. ^{[1] [9] [10]}

Statins are typically first-line for LDL-C elevation in solid organ transplant recipients, but should be initiated and titrated with attention to drug–drug interactions (notably with calcineurin inhibitors and some lipid agents). For marked hypertriglyceridemia, fibrates may be considered with careful monitoring (renal function and myopathy risk, especially if combined with a statin). Omega-3 fatty acids or icosapent ethyl can be considered as adjuncts for elevated triglycerides per clinician judgment. Coordinate changes with transplant hepatology/nephrology and cardiology when appropriate. ^{[9] [10] [11]}

Lifestyle measures remain foundational: reduce saturated/trans fats, increase soluble fiber, emphasize fish/omega-3 sources, limit alcohol (particularly for triglycerides), and pursue weight management and activity as cleared post-transplant. Address contributors such as uncontrolled diabetes or hypothyroidism, and review supplements for interaction risk. In high-risk cases, aggressive triglyceride control is important to reduce pancreatitis risk, while still maintaining safe immunosuppressant exposure. ^{[9] [12]}

Repeat lipids after therapy changes to confirm response. If dyslipidemia remains severe despite optimized therapy, reassess exposure targets and interactions and consider whether immunosuppression modification is warranted—always under transplant-team supervision with close graft monitoring. ^{[1] [8] [10]}

Everolimus exposure can increase substantially with strong CYP3A inhibitors; ketoconazole is a classic example that markedly raises everolimus blood concentrations. Because both immunosuppressants and several statins share CYP3A metabolism, interaction-aware prescribing is essential to reduce toxicity risks (including myopathy with certain statins and elevated immunosuppressant exposure). Transplant labeling also instructs patients to avoid grapefruit products, which can increase everolimus levels. Patients should contact the transplant team before starting new prescription drugs, OTC products, or supplements. ^{[2] [1] [10] [11]}

When dyslipidemia persists despite optimized lifestyle measures and appropriate lipid-lowering therapy, the transplant team may consider adjusting the immunosuppressive regimen (dose or target trough changes, or alternative regimens). Decisions must be individualized, balancing cardiovascular risk reduction against infection risk, renal function, and rejection risk, with close laboratory and clinical follow-up. Published liver-transplant consensus and practice reviews emphasize structured adverse-event management for everolimus, including metabolic complications, within center protocols. ^{[8] [3]}

• Explain why lipids can rise on mTOR inhibitors and how they’ll be monitored (baseline and follow-up lipid panels). ^[1]
• Reinforce diet, activity, and adherence to lipid-lowering therapy; “no symptoms” does not mean lipids are controlled. ^[9]
• Review interaction risks, including OTC/supplements and grapefruit products; instruct patients to call before starting new meds. ^{[1] [2] [11]}
• Provide clear thresholds for when to contact the team (new muscle pain/weakness, dark urine, severe GI symptoms, new meds, or rapid lab changes). ^[11]
• Emphasize that immunosuppression should never be adjusted without the transplant team, even if lipid numbers are high. ^[1]

1. Novartis. Zortress® (everolimus) Prescribing Information (PDF) — includes hyperlipidemia warning and monitoring guidance.
2. Kovarik JM, et al. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol. 2005;45(5):514–518. (Interaction magnitude; CYP3A inhibition example)
3. Yee ML, et al. Use of everolimus in liver transplantation. World J Hepatol. 2017. (Review; place in therapy and adverse-event considerations)
4. Kniepeiss D, et al. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Transpl Int. 2004. (Liver transplant cohort experience)
5. Gisbert C, et al. Hyperlipidemia in liver transplant recipients. Transplant Proc. 1997. (Post-transplant dyslipidemia epidemiology context)
6. Saliba F, et al. Conversion to everolimus in maintenance liver transplant patients: indications, exposure, efficacy and safety. Liver Transpl. 2011.
7. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs. 2007;67(3):369–391. (Class overview; adverse effects including hyperlipidemia)
8. De Simone P, et al. Use of Everolimus in Liver Transplantation (consensus/practice statements). Liver Transpl. 2017.
9. Mehta A, et al. Managing dyslipidemia in solid organ transplant patients. (Review; statins first-line; interaction cautions) 2024.
10. National Lipid Association. Management of Statin Treatment in Adult Solid Organ Transplant Recipients (interaction-focused practical guidance). 2018.
11. Wiggins BS, et al. AHA Scientific Statement: Recommendations for management of clinically significant drug–drug interactions with statins. Circulation. 2016.
12. Lo P, et al. Severe hypertriglyceridemia associated with everolimus (case report; illustrates monitoring importance). AACE Clinical Case Reports. 2020.